Until now, it was advised that efavirenz, a widely-used anti-retroviral drug for the treatment of HIV, be avoided during pregnancy. New draft UK guidelines on the treatment of HIV in pregnancy no longer recommend that efavirenz (Sustiva, also part of the combination pill Atripla) should be avoided by pregnant women and women hoping to become pregnant. This means that women who are hoping to become pregnant can continue to take efavirenz, as can women who become pregnant.

More information on this, and on other matters relating to HIV treatment in pregnancy, can be found here.